Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 279

1.

Impact of systemic and tumor lipid metabolism on everolimus efficacy in advanced pancreatic neuroendocrine tumors (pNETs).

Vernieri C, Pusceddu S, Fucà G, Indelicato P, Centonze G, Castagnoli L, Ferrari E, Ajazi A, Pupa S, Casola S, Foiani M, Mazzaferro V, Pruneri G, Milione M, de Braud F.

Int J Cancer. 2018 Dec 5. doi: 10.1002/ijc.32042. [Epub ahead of print]

PMID:
30520016
2.

Hepatocellular Carcinoma in Abernethy Malformation: A Rare Occurrence of Congenital Complete Portosystemic Shunt.

Virdis M, Monteleone M, Sposito C, Cascella T, Pellegrinelli A, Mazzaferro V.

J Vasc Interv Radiol. 2018 Dec;29(12):1775-1778. doi: 10.1016/j.jvir.2018.07.014. No abstract available.

PMID:
30502882
3.

Endo-therapies for biliary duct-to-duct anastomotic stricture after liver transplantation: outcomes of a nationwide survey.

Cantù P, Tarantino I, Baldan A, Mutignani M, Tringali A, Lombardi G, Cerofolini A, Di Sario A, Catalano G, Bertani H, Ghinolfi D, Boarino V, Masci E, Bulajic M, Pisani A, Fantin A, Ligresti D, Barresi L, Traina M, Ravelli P, Forti E, Barbaro F, Costamagna G, Rodella L, Maroni L, Salizzoni M, Conigliaro R, Filipponi F, Merighi A, Staiano T, Monteleone M, Mazzaferro V, Zucchi E, Zilli M, Nadal E, Rosa R, Santi G, Parzanese I, De Carlis L, Donato MF, Lampertico P, Maggi U, Caccamo L, Rossi G, Vecchi M, Penagini R.

Liver Int. 2018 Nov 30. doi: 10.1111/liv.14010. [Epub ahead of print]

PMID:
30500104
4.

Derazantinib (ARQ 087) in advanced or inoperable FGFR2 gene fusion-positive intrahepatic cholangiocarcinoma.

Mazzaferro V, El-Rayes BF, Droz Dit Busset M, Cotsoglou C, Harris WP, Damjanov N, Masi G, Rimassa L, Personeni N, Braiteh F, Zagonel V, Papadopoulos KP, Hall T, Wang Y, Schwartz B, Kazakin J, Bhoori S, de Braud F, Shaib WL.

Br J Cancer. 2018 Nov 13. doi: 10.1038/s41416-018-0334-0. [Epub ahead of print]

PMID:
30420614
5.

Multicenter validation of a score to predict prognosis after the development of HCC recurrence following liver transplantation.

Goldaracena N, Mehta N, Scalera I, Sposito C, Atenafu EG, Yao FY, Muiesan P, Mazzaferro V, Sapisochin G.

HPB (Oxford). 2018 Oct 31. pii: S1365-182X(18)34478-2. doi: 10.1016/j.hpb.2018.10.005. [Epub ahead of print]

PMID:
30391218
6.

Ki-67 and presence of liver metastases identify different progression-risk classes in pancreatic neuroendocrine neoplasms (pNEN) undergoing resection.

Milione M, Maisonneuve P, Pellegrinelli A, Spaggiari P, Centonze G, Coppa J, Delconte G, Droz Dit Busset M, Lanhazo O, Pruneri G, Mazzaferro V.

Eur J Surg Oncol. 2018 Oct 11. pii: S0748-7983(18)31452-5. doi: 10.1016/j.ejso.2018.10.052. [Epub ahead of print]

PMID:
30366875
7.

Systemic Administration and Targeted Delivery of Immunogenic Oncolytic Adenovirus Encapsulated in Extracellular Vesicles for Cancer Therapies.

Garofalo M, Villa A, Rizzi N, Kuryk L, Mazzaferro V, Ciana P.

Viruses. 2018 Oct 13;10(10). pii: E558. doi: 10.3390/v10100558.

8.

Development of pre and post-operative models to predict early recurrence of hepatocellular carcinoma after surgical resection.

Chan AWH, Zhong J, Berhane S, Toyoda H, Cucchetti A, Shi K, Tada T, Chong CCN, Xiang BD, Li LQ, Lai PBS, Mazzaferro V, García-Fiñana M, Kudo M, Kumada T, Roayaie S, Johnson PJ.

J Hepatol. 2018 Dec;69(6):1284-1293. doi: 10.1016/j.jhep.2018.08.027. Epub 2018 Sep 18.

9.

Laparoscopic liver resection of hepatocellular carcinoma located in unfavorable segments: a propensity score-matched analysis from the I Go MILS (Italian Group of Minimally Invasive Liver Surgery) Registry.

Levi Sandri GB, Ettorre GM, Aldrighetti L, Cillo U, Dalla Valle R, Guglielmi A, Mazzaferro V, Ferrero A, Di Benedetto F, Gruttadauria S, De Carlis L, Vennarecci G; I Go MILS Group on HCC.

Surg Endosc. 2018 Sep 10. doi: 10.1007/s00464-018-6426-3. [Epub ahead of print]

PMID:
30203200
10.

Molecular predictors of prevention of recurrence in HCC with sorafenib as adjuvant treatment and prognostic factors in the phase 3 STORM trial.

Pinyol R, Montal R, Bassaganyas L, Sia D, Takayama T, Chau GY, Mazzaferro V, Roayaie S, Lee HC, Kokudo N, Zhang Z, Torrecilla S, Moeini A, Rodriguez-Carunchio L, Gane E, Verslype C, Croitoru AE, Cillo U, de la Mata M, Lupo L, Strasser S, Park JW, Camps J, Solé M, Thung SN, Villanueva A, Pena C, Meinhardt G, Bruix J, Llovet JM.

Gut. 2018 Aug 14. pii: gutjnl-2018-316408. doi: 10.1136/gutjnl-2018-316408. [Epub ahead of print]

11.

Should a History of Extraperitoneal Disease Be a Contraindication to Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy for Colorectal Cancer Peritoneal Metastases?

Baratti D, Kusamura S, Iusco D, Cotsoglou C, Guaglio M, Battaglia L, Virzì S, Mazzaferro V, Deraco M.

Dis Colon Rectum. 2018 Sep;61(9):1026-1034. doi: 10.1097/DCR.0000000000001156.

PMID:
30086051
12.

Liver Transplantation and Hepatic Resection can Achieve Cure for Hepatocellular Carcinoma.

Pinna AD, Yang T, Mazzaferro V, De Carlis L, Zhou J, Roayaie S, Shen F, Sposito C, Cescon M, Di Sandro S, Yi-Feng H, Johnson P, Cucchetti A.

Ann Surg. 2018 Nov;268(5):868-875. doi: 10.1097/SLA.0000000000002889.

PMID:
30080736
13.

Trans-arterial radioembolization for intermediate-advanced hepatocellular carcinoma: a budget impact analysis.

Rognoni C, Ciani O, Sommariva S, Bargellini I, Bhoori S, Cioni R, Facciorusso A, Golfieri R, Gramenzi A, Mazzaferro V, Mosconi C, Ponziani F, Sacco R, Trevisani F, Tarricone R.

BMC Cancer. 2018 Jul 5;18(1):715. doi: 10.1186/s12885-018-4636-7.

14.

Phase II Studies with Refametinib or Refametinib plus Sorafenib in Patients with RAS-Mutated Hepatocellular Carcinoma.

Lim HY, Merle P, Weiss KH, Yau T, Ross P, Mazzaferro V, Blanc JF, Ma YT, Yen CJ, Kocsis J, Choo SP, Sukeepaisarnjaroen W, Gérolami R, Dufour JF, Gane EJ, Ryoo BY, Peck-Radosavljevic M, Dao T, Yeo W, Lamlertthon W, Thongsawat S, Teufel M, Roth K, Reis D, Childs BH, Krissel H, Llovet JM.

Clin Cancer Res. 2018 Oct 1;24(19):4650-4661. doi: 10.1158/1078-0432.CCR-17-3588. Epub 2018 Jun 27.

PMID:
29950351
15.

A Longitudinal Investigation of Posttraumatic Growth and Quality of Life in Liver Transplant Recipients.

Gangeri L, Scrignaro M, Bianchi E, Borreani C, Bhoorie S, Mazzaferro V.

Prog Transplant. 2018 Sep;28(3):236-243. doi: 10.1177/1526924818781569. Epub 2018 Jun 26.

PMID:
29945480
16.

pH regulators to target the tumor immune microenvironment in human hepatocellular carcinoma.

Kuchuk O, Tuccitto A, Citterio D, Huber V, Camisaschi C, Milione M, Vergani B, Villa A, Alison MR, Carradori S, Supuran CT, Rivoltini L, Castelli C, Mazzaferro V.

Oncoimmunology. 2018 Mar 26;7(7):e1445452. doi: 10.1080/2162402X.2018.1445452. eCollection 2018.

17.

Reply.

Sposito C, Cucchetti A, Mazzaferro V.

Gastroenterology. 2018 Jun;154(8):2276-2277. doi: 10.1053/j.gastro.2018.05.014. Epub 2018 May 8. No abstract available.

PMID:
29750911
18.

Entering the third decade of experience with octreotide LAR in neuroendocrine tumors: A review of current knowledge.

Pusceddu S, Prinzi N, Raimondi A, Corti F, Buzzoni R, Di Bartolomeo M, Seregni E, Maccauro M, Coppa J, Milione M, Mazzaferro V, de Braud F.

Tumori. 2018 Apr 1:300891618765362. doi: 10.1177/0300891618765362. [Epub ahead of print]

PMID:
29714658
19.

Reply to: "Validation of response to yttrium-90 radioembolization for hepatocellular carcinoma with portal vein invasion".

Sposito C, Spreafico C, Mazzaferro V.

J Hepatol. 2018 Jul;69(1):260-261. doi: 10.1016/j.jhep.2018.04.008. Epub 2018 Apr 27. No abstract available.

PMID:
29705239
20.

Hepatocellular carcinoma is associated with gut microbiota profile and inflammation in nonalcoholic fatty liver disease.

Ponziani FR, Bhoori S, Castelli C, Putignani L, Rivoltini L, Del Chierico F, Sanguinetti M, Morelli D, Paroni Sterbini F, Petito V, Reddel S, Calvani R, Camisaschi C, Picca A, Tuccitto A, Gasbarrini A, Pompili M, Mazzaferro V.

Hepatology. 2018 Apr 17. doi: 10.1002/hep.30036. [Epub ahead of print]

PMID:
29665135

Supplemental Content

Loading ...
Support Center